Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Giulio Cerea
Observed names:
Cerea, Giulio,
G Cerea,
G. Cerea
Institution:
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
Observed institutions:
Memorial Sloan Kettering Cancer Center,
University of Milan,
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico,
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda,
Azienda Ospedaliera San Gerardo
ORCID:
0000-0003-1133-0681
Observed ORCID:
0000-0003-1133-0681
OpenAlex ID:
A5091886023
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)
2017
·
Alexander Drilon
, Salvatore Siena
, et al.
·
Cancer Discovery
·
885
PDF
Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study
2024
·
Luis G. Paz-Ares
, Oscar Juan-Vidal
, et al.
·
Journal of Clinical Oncology
·
174
PDF
First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status
2020
·
Francesco Facchinetti
, Giulia Mazzaschi
, et al.
·
European Journal of Cancer
·
153
PDF
Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations.
2003
·
G Cerea
, M Vaghi
, et al.
·
PubMed
·
109
Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer
2015
·
Alessio Amatu
, Alessio Somaschini
, et al.
·
British Journal of Cancer
·
88
PDF
Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations
2018
·
Antonio Passaro
, Arsela Prelaj
, et al.
·
Clinical Lung Cancer
·
60
Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study
2011
·
C. Gridelli
, F. Morgillo
, et al.
·
Annals of Oncology
·
58
Alka-372-001: First-in-human, phase I study of entrectinib – an oral pan-trk, ROS1, and ALK inhibitor – in patients with advanced solid tumors with relevant molecular alterations.
2015
·
Filippo G. De Braud
, Monica Niger
, et al.
·
Journal of Clinical Oncology
·
56
Entrectinib for the treatment of metastatic NSCLC: safety and efficacy
2020
·
Andrea Sartore-Bianchi
, Elio Gregory Pizzutilo
, et al.
·
Expert Review of Anticancer Therapy
·
52
PDF
Liquid Biopsy for Prognosis and Treatment in Metastatic Colorectal Cancer: Circulating Tumor Cells vs Circulating Tumor DNA
2021
·
Giorgio Patelli
, Caterina Vaghi
, et al.
·
Targeted Oncology
·
43
PDF
Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer
2016
·
Federico Cappuzzo
, Alessandro Morabito
, et al.
·
Lung Cancer
·
39
Phase 1 open label, dose escalation study of RXDX101, an oral pan-trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations.
2014
·
Filippo G. De Braud
, Lorenzo Pilla
, et al.
·
Journal of Clinical Oncology
·
34
Phase II Randomized Study of Vandetanib Plus Gemcitabine or Gemcitabine Plus Placebo as First-Line Treatment of Advanced Non–Small-Cell Lung Cancer in Elderly Patients
2014
·
Cesare Gridelli
, Silvia Novello
, et al.
·
Journal of Thoracic Oncology
·
33
PDF
Treatment of metastatic neuroendocrine carcinomas based on WHO classification.
2005
·
Salvatore Artale
, Laura Giannetta
, et al.
·
PubMed
·
33
A multicenter, single-arm, basket design, phase II study of NC-6004 plus gemcitabine in patients with advanced unresectable lung, biliary tract, or bladder cancer
2020
·
Simona Ruxandra Volovat
, Tudor-Eliade Ciuleanu
, et al.
·
Oncotarget
·
32
PDF
Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients Aged ≥ 75 Years With Non–small-cell Lung Cancer (NSCLC): An Italian, Multicenter, Retrospective Study
2020
·
Andrea Luciani
, Antonio Marra
, et al.
·
Clinical Lung Cancer
·
31
Sotorasib in KRASp.G12C mutated advanced NSCLC: Real-world data from the Italian expanded access program
2023
·
Francesco Passiglia
, Maria Lucia Reale
, et al.
·
Lung Cancer
·
30
PDF
Eosinophilic myocarditis: a paraneoplastic event
2015
·
Enrico Ammirati
, Miriam Stucchi
, et al.
·
The Lancet
·
29
Liquid Biopsy for Small Cell Lung Cancer either De Novo or Transformed: Systematic Review of Different Applications and Meta-Analysis
2021
·
Elio Gregory Pizzutilo
, Martino Pedrani
, et al.
·
Cancers
·
28
PDF
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study
2020
·
Melissa Bersanelli
, Sebastiano Buti
, et al.
·
Lung Cancer
·
27
PDF
Rationale and Clinical Results of Multi-target Treatments in Oncology
2007
·
A. Sartore-Bianchi
, R. Ricotta
, et al.
·
The International Journal of Biological Markers
·
26
A phase II basket study of MCLA-128, a bispecific antibody targeting the HER3 pathway, in NRG1 fusion-positive advanced solid tumors.
2020
·
Alison M. Schram
, Alexander E. Drilon
, et al.
·
Journal of Clinical Oncology
·
25
Cetuximab for treatment of metastatic colorectal cancer
2006
·
G. Cerea
, R. Ricotta
, et al.
·
Annals of Oncology
·
24
Activity of osimeRTInib in non-small-cell lung Cancer with UNcommon epidermal growth factor receptor mutations: retrospective Observational multicenter study (ARTICUNO)
2024
·
E.G. Pizzutilo
, A.G. Agostara
, et al.
·
ESMO Open
·
22
PDF
Immune Checkpoint Inhibitors and the Exposome: Host-Extrinsic Factors Determine Response, Survival, and Toxicity
2023
·
Elio Gregory Pizzutilo
, Rebecca Romanò
, et al.
·
Cancer Research
·
20
PDF
Show more works
View as search
Works count:
74
Citation count:
2,272
H-index:
23
I10-index:
30
Year
Topic
Type